Thymosin Alpha-1 dosage: what the studies administered, by population and route

Start here

This page describes the Thymosin Alpha-1 dosage figures that appear in published studies — and only those. Nothing here is a recommendation, and no one should read it as one. In plain terms: researchers and clinicians abroad have given the peptide as a small injection under the skin (subcutaneous), usually a couple of times a week for chronic hepatitis, or more often for short, intensive courses in hospital settings like sepsis. The amounts are measured in milligrams. The peptide clears the body fairly quickly — its level roughly halves within about two hours of a shot. Because it is not approved in the US and is not something this site endorses for personal use, every number below is written as what was studied in which patients, by which route. The point is to summarize the literature accurately, not to tell anyone what to do.

Thymosin alpha 1 dosage in the literature

A comprehensive review of four decades of clinical literature reports that the standard single subcutaneous dose of the peptide ranges from 0.8 to 6.4 mg, with multiple-dose regimens of 1.6 to 16 mg given over five to seven days ^[4]. The recurring figure across most indications is a 1.6 mg unit dose — the same per-injection amount appears whether the schedule is twice weekly or every twelve hours, with the indication setting the frequency and duration rather than the size of each shot.

Across the trials, the recurring regimens were: 1.6 mg subcutaneous twice weekly — the standard chronic-hepatitis B/C protocol ^[4]; 1.6 mg subcutaneous every 12 hours for 5 to 7 days in the sepsis trials (ETASS used 1.6 mg every 12 hours for 5 days then once daily for 2 days; the null TESTS used 1.6 mg every 12 hours for 7 days) ^[2][3]; and 1.6 mg subcutaneous daily in the COVID-19 cohort work ^[6]. All clinical administration in essentially every trial was by subcutaneous injection. These are reported strictly as study parameters in specified patient populations — not as guidance for any individual.

Dosing varied by indication, not by preference

A useful way to read the numbers is that frequency tracks how urgent the immune problem is. In chronic viral hepatitis — a slow, long-running condition — the studied schedule was a low-frequency 1.6 mg twice-weekly course sustained over months, with the chronic hepatitis B combination trials running the peptide alongside oral antivirals such as lamivudine or entecavir ^[9][10]. In acute, life-threatening sepsis the studied schedule compressed to 1.6 mg every twelve hours for under a week, front-loading exposure during the critical window ^[2][3]. The COVID-19 cohort work sat between these, using 1.6 mg once daily across the acute illness ^[6]. The same per-dose amount, very different cadences — and the most rigorous of these settings, sepsis, ultimately showed no mortality benefit at that dose and schedule ^[3]. None of this is a template for self-administration; it is the shape of how the compound was studied.

Thymosin alpha 1 injection: route, half-life, and handling

Every major clinical study used subcutaneous injection as the route; in vitro, ex vivo, and murine models cover the mechanistic and preclinical work. After a subcutaneous dose in human volunteers the peptide shows an elimination half-life of roughly two hours, with blood levels peaking around one to two hours and returning toward baseline within about 24 hours; its volume of distribution is consistent with distribution into extracellular fluid. Pharmacologically it is a highly acidic peptide (isoelectric point about 4.2) that does not bind plasma proteins extensively and is degraded by tissue and circulating aminopeptidases; it is supplied lyophilized (freeze-dried), and its N-terminal acetylation is required for activity ^[4]. None of this constitutes a preparation or self-administration instruction — it is the pharmacology of record.

The short, roughly two-hour half-life helps explain why the trial schedules look the way they do: in acute settings the peptide was given as often as every twelve hours to maintain exposure, while the chronic-hepatitis schedule relied on the immunological effect outlasting the peptide's brief presence in the blood ^[4]. Among community users, the practical friction points reported are not pharmacological at all — they are the cost, the limited access outside approved markets, and the uncertainty of reconstituting a lyophilized research-grade vial correctly. Those are access and handling issues, not properties of the molecule, and they fall outside anything this site can advise on.

The human clinical context

Four decades of international human data — dozens of randomized trials and large post-marketing surveillance — span chronic hepatitis B and C, sepsis, severe acute pancreatitis, COVID-19, HIV immune reconstitution, vaccine augmentation, and cancer-adjuvant settings ^[4]. Efficacy signals are strongest and most consistent in chronic viral hepatitis and as an immune-restorative adjunct; the largest rigorous sepsis RCT was null ^[3]. Marketed dosing and outcomes derive from approved-abroad clinical settings, and extrapolating them to unregulated or self-administered use is not supported by the evidence and falls outside any approved indication.